Randall Carpenter, MD, Principal Investigator
Seaside Therapeutics
Mark Bear, Ph.D. Co-Investigator
Mass. Institute of Technology (MIT)

FRAXA Awards:
  $10,000 in 2007
towards a large multi-year grant from NIMH

by Katie Clapp, FRAXA, 5/2007

Seaside Therapeutics was founded by Dr.Mark Bear, Director of the Picower Institute at MIT, and Dr. Randall Carpenter, a physician with many years of drug development experience. Seaside has received a major grant from the NIH, with additional funding from FRAXA and Cure Autism Now (CAN).

Seaside has licensed from Merck several selective, potent mGluR5 antagonists. They intend to develop the lead compound, STX107, to treat Fragile X and, potentially, autism. They will advance the compound through the preclinical studies necessary to fulfill FDA requirements to open an Investigational New Drug application and perform initial testing in humans.